Should You Buy Global Blood Therapeutics Before This Week's Earnings?

Global Blood Therapeutics (NASDAQ: GBT) plans to report its first quarter earnings on Wednesday, May 6. Importantly, investors will see the first full quarter of sales for Oxbryta, the company's recently approved drug for adults and children age 12 and older with sickle cell disease.

Image Source: Getty Images.

The Food and Drug Administration (FDA) approved Oxbryta on Nov. 25., three months before the FDA's Priority Review action date for the decision. Global Blood got the once-a-day oral treatment in the hands of specialty pharmacy distributors within days of the approval. The initial sales through the last few weeks of 2019 generated a meager $2.1 million.

Continue reading

Source Fool.com